RxDoctor Payments Data

Allison Ernest

Psychiatric/Mental Health · Richmond, VANPI 1235762964

Payments from drug & device makers

$4,829in general payments, 2019–2025

Across 227 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$894
  • Neurocrine Biosciences, Inc.$803
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$638
  • Sunovion Pharmaceuticals Inc.$556
  • Otsuka America Pharmaceutical, Inc.$343
  • Johnson & Johnson$330
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,77399%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,829 in reported general payments places this provider in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$30,226
Medicare patients
38
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl16$25,368
CaplytaLumateperone Tosylate11$18,227
Aripiprazole22$2,304
Venlafaxine Hcl ErVenlafaxine Hcl28$1,288
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine20$1,235
Bupropion XlBupropion Hcl42$947
Quetiapine Fumarate51$777
Trazodone Hcl62$577
Lamotrigine28$460
Buspirone Hcl39$379
Propranolol Hcl15$370
Mirtazapine15$361
Duloxetine Hcl11$354
Gabapentin29$353
Clonazepam57$335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$894$25,36816 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$638$18,22711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →